CompletedPhase 3NCT03120949
Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis
Studying NON RARE IN EUROPE: Rheumatoid arthritis
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- R-Pharm International, LLC
- Principal Investigator
- Mikhail SamsonovChief Medical Officer, R-Pharm
- Intervention
- Olokizumab 64 mg SC q4w(drug)
- Enrollment
- 2106 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2017 – 2021
Study locations (30)
- AZ Arthritis & Rheum' Research, Mesa, Arizona, United States
- Arizona Arthritis & Rheumatology Associates, P.C., Phoenix, Arizona, United States
- Arizona Arthritis & Rheumatology Research, PLLC, Sun City, Arizona, United States
- CHI St. Vincent Hot Springs, Hot Springs, Arkansas, United States
- Medvin Clinical Research, Covina, California, United States
- C.V Mehta MD Med Corp.., Hemet, California, United States
- Advanced Medical Research, LLC, La Palma, California, United States
- Valerius Medical Group, Los Alamitos, California, United States
- Stanford University School of Medicine, Palo Alto, California, United States
- Rheumatology Center of San Diego, San Diego, California, United States
- East Bay Rheumatology Medical Group, Inc., San Leandro, California, United States
- Inland Rheumatology Clinical Trials, Inc., Upland, California, United States
- Center for Rheumatology Research, Comprehensive Rheumatology Center, West Hills, California, United States
- Medvin Clinical Research, Whittier, California, United States
- Denver Arthritis Clinic, Denver, Colorado, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
IQVIA Pvt. Ltd · OCT Clinical Trials
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03120949 on ClinicalTrials.govOther trials for NON RARE IN EUROPE: Rheumatoid arthritis
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07137598A Study to Assess the Efficacy and Safety of RO7790121 in Participants With Moderate to Severe Rheumatoid Arthritis Who Have Not Responded to or Who Cannot Tolerate Tumor Necrosis Factor (TNF) and/or Janus Kinase (JAK Inhibitors)Hoffmann-La Roche
- RECRUITINGPHASE1NCT07200596The Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of SHR-3045 in Healthy SubjectsGuangdong Hengrui Pharmaceutical Co., Ltd
- RECRUITINGPHASE2NCT07100938A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid ArthritisBeiGene
- RECRUITINGPHASE1NCT07040930Assessment of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Multiple Subcutaneous Injections of GenSci120 in Healthy Adult Participants in China.Changchun GeneScience Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07089381Efficacy and Safety of Resveratrol in Patients With Rheumatoid Arthritis.Ain Shams University
- RECRUITINGNANCT06693479Could a Feedback Device Help Manage Work-related Shoulder Disorders?Laval University
- ACTIVE NOT RECRUITINGPHASE1, PHASE2NCT06475495Comparison of B-cell Depletion by Rituximab and Anti-CD 19 CAR-T Therapy in Patients With Rheumatoid ArthritisCharite University, Berlin, Germany
- RECRUITINGNCT07315997The Coronary Artery Calcium and Troponins in Rheumatoid Arthritis (CAT-RA) StudyBrigham and Women's Hospital
See all trials for NON RARE IN EUROPE: Rheumatoid arthritis →